Evidence map›Paper›PMID 41940628›Full record

ArticleFuture oncology (London, England)2026

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in

Solange Peters, Maximilian Hochmair, Kathryn C Arbour, Luis Paz-Ares Rodriguez, Martin Reck, Ticiana Leal, Colin R Lindsay, Lu Shun, William Nassib William, Alexander I Spira and 10 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06119581 (SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06119581 phase3recruitingnot on this map

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

TypeinterventionalSponsorEli Lilly and CompanyRan2023 to 2031Enrolled1,264ConditionsCarcinoma, Non-Small-Cell Lung, Neoplasm MetastasisArmsLY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Solange PetersOncology Department, Lausanne University and CHUV, Lausanne, Switzerland.
Maximilian HochmairDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Kathryn C ArbourDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Luis Paz-Ares RodriguezMedical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain.
Martin ReckDepartment of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Grosshansdorf, Germany.
Ticiana LealDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Colin R LindsayDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Lu ShunShangai Lung Cancer Centre, Shanghai Chest Hospital, School of Medicine, Shangai Jiaotong University, Shanghai, China.
William Nassib WilliamGrupo Oncoclínicas, São Paulo, Brazil.
Alexander I SpiraVirginia Cancer Specialists, Fairfax, VA, USA.
Joshua K SabariPerlmutter Cancer Centre, NYU Langone Health, New York, NY, USA.
Bjørn Henning GrønbergDepartment of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Makoto NishioDepartment of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Timothy F BurnsDepartment of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Colombus, OH, USA.
Nicolas GirardInstitut du Thorax Curie Montsouris, Institut Curie, Paris, France.
Frederico CapuzzoMedical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Alyson MercedEli Lilly and Company, Indianapolis, IN, USA.
Nicolas FasnachtEli Lilly and Company, Indianapolis, IN, USA.
Carla Visseren-GrulEli Lilly and Company, Indianapolis, IN, USA.
Marcelo V NegraoDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

CLINICAL

trial registrationwww.clinicaltrials.gov identifier is NCT06119581. EudraCT: 2023-503412-33-00.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins p21(ras)Clinical Trials, Phase III as TopicHumansMutationAntibodies, Monoclonal, HumanizedKRAS protein, humanpembrolizumabProto-Oncogene Proteins p21(ras)first-line treatmentKRASNSCLColomorasibpembrolizumabphase III trialStudy designtreatment rationale

Identifiers

PMID41940628
PMCPMC13064562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.